These Analysts Revise Their Forecasts On Elevance Health Following Q2 Earnings

Category: Markets

Published: 2026-07-16T12:17:55.000Z

Elevance Health (NYSE: ELV) reported strong Q2 results, surpassing analyst expectations for earnings and revenue, and subsequently raised its full-year guidance for 2026. Following these positive results, several analysts, including those from Baird, Barclays, and Guggenheim, adjusted their price targets for Elevance Health shares. The company's stock rose 1.8% in pre-market trading after the announcement.

Read the original source

News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.